Depolarizing Blockers
Depolarizing Blockers - Related Videos
01:19
Depolarizing Blockers: Pharmocokinetics
0 Views •
2023
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:28
Depolarizing Blockers: Mechanism of Action
0 Views •
2023
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes. Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
03:06
Investigating Prolonged Depolarizing Afterpotential (PDA) in Drosophila Photoreceptors
0 Views •
2025
This video demonstrates an experimental protocol to investigate the prolonged depolarizing afterpotential (PDA) in white-eyed Drosophila. The fly's eye is exposed to intense blue light pulses to convert the photopigment rhodopsin to metarhodopsin, initiating a signaling cascade that opens positive ion channels and causes membrane depolarization. Because blue light prevents the reconversion of metarhodopsin to rhodopsin, the continuous influx of positive ions results in sustained depolarization,...
02:08
Assessing Muscle Contraction with Neuromuscular Blocker Treatment
0 Views •
2025
This video demonstrates assessing the muscle using cultured motor neurons, Schwann cells, and myotubes, followed by treatment with a neuromuscular blocker to inhibit contraction. Color-coded time-motion graphics show a color-coded time-motion graphic. Red indicates the fastest movement, and blue indicates the slowest.
03:16
Intravenous Delivery of Receptor Blockers to Reduce Brain Edema in a Mouse Model
0 Views •
2025
Source: Zeynalov, E. et. al., Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema. J. Vis. Exp. (2016)This video demonstrates the intravenous delivery of an arginine-vasopressin (AVP) receptor antagonist in a mouse model. Transient middle cerebral artery occlusion induces brain edema. An AVP receptor antagonist is administered through a catheter in the left jugular vein, alleviating edema.
FAQs
After binding nicotinic acetylcholine receptors at the motor end plate, these drugs maintain the muscle membrane in a depolarized state. This keeps nearby voltage-gated sodium channels inactivated, so they cannot support another action potential. Without repeated action potentials, neuromuscular transmission fails and skeletal muscle contraction cannot continue, producing the intended temporary paralysis.
Prolonged exposure can change the initial depolarizing block into a desensitization, or phase II, block. In this state, the neuromuscular junction becomes less responsive even though the drug has continued to act at the receptor. Recognizing this transition matters because the pattern reflects a different functional state from the initial sustained depolarization.
Sodium channels normally help propagate the electrical signal required for skeletal muscle contraction. Persistent end-plate depolarization leaves these channels in an inactivated state, preventing subsequent action potentials from forming or propagating effectively. This links receptor binding at the neuromuscular junction to the broader physiological outcome of muscle paralysis.
Their ability to produce skeletal muscle paralysis makes them useful when clinicians need to facilitate rapid tracheal intubation. The same pharmacologic effect can provide short-term muscle relaxation during procedures. Because paralysis can interfere with spontaneous breathing and may persist under some conditions, their use requires attention to the duration and intensity of the response.
Important concerns include prolonged apnea, hyperkalemia, and malignant hyperthermia in susceptible patients. These risks explain why administration requires careful monitoring rather than relying only on the expected paralytic effect. Monitoring helps clinicians recognize an excessive or dangerous response and supports safer use during intubation or short procedures.
Malignant hyperthermia is identified in the source as a possible adverse response in susceptible patients receiving depolarizing blockers. This makes patient susceptibility an important part of pharmacologic risk assessment before use. The concern is especially relevant when the drugs are selected for rapid airway management or procedural muscle relaxation, where prompt recognition of complications is essential.